Name:

Coagyl® VII

Alternative name:

Human blood coagulation factor VII

Type of medical product:

Protein based

Novelty:

Biosimilar

Field:

Congenital diseases

Indications for use:

Haemophilia type A

Status:

Registered

Recombinant activated coagulation factor VII is a biosimilar of Novoseven® (Novo Nordisk). It is identical in structure to human factor VIIa present in the plasma. It is produced by genetically engineered baby hamster kidney (BHK) cells. Pharmacodynamic effect of this biologic is in the enhancement of local concentration of coagulation factor Xa followed by an acceleration of synthesis in the enzymatic cascade reactions producing thrombin and fibrin.

It is administered to stop and prevent bleeding during surgery in patients with hereditary or inhibitor haemophilia, type A and type B and Glanzmann’s thrombasthenia. It is a universal haemostatic agent, there are descriptions of cases where it was successfully applied to stop major bleeding in non- haemophilia cases, including liver failure, major surgery, multiple trauma, postpartum haemorrhage, and more.

The wide medical use of the foreign analogue of the coagulation factor VII in Russia is limited due to its high cost. The introduction of domestically manufactured coagulation factor VII in the standard medical practice for massive bleeding can increase the effectiveness of the treatment and reduce mortality from blood loss by 85%.

Our Partners:

  • CJSC “Generium”